Skip to content

Sivelestat sodium

DRUG9 trials

Sponsors

Sichuan Provincial People's Hospital, Southeast University, China, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, The First Hospital of Jilin University

Conditions

ARDSARDS Due to Disease Caused by SARS Co-V-2Acute Ischemic StrokeAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Acute Respiratory Distress SyndromeAortic DissectionInflammatory ResponseLarge Vessel Occlusion

Phase 3

Phase 4

Unknown Phase

Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
NCT05020210
Nanfang Hospital, Southern Medical UniversityARDS, Inflammatory Response
Start: 2021-09-30End: 2023-08-31Target: 560Updated: 2022-12-21
Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium
NCT05343338
First Affiliated Hospital Xi'an Jiaotong UniversityAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Aortic Dissection
Start: 2022-04-20End: 2024-12-31Target: 168Updated: 2022-04-25
Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis
NCT05672472
The First Hospital of Jilin UniversityAcute Respiratory Distress Syndrome
Start: 2023-01-10End: 2025-02-10Target: 100Updated: 2023-01-05
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
CompletedNCT06218862
The First Hospital of Jilin UniversityARDS Due to Disease Caused by SARS Co-V-2
Start: 2022-12-01End: 2023-05-31Updated: 2024-01-23
Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS
RecruitingNCT06387823
Peking Union Medical College HospitalAcute Respiratory Distress Syndrome
Start: 2024-04-15End: 2025-09-01Target: 300Updated: 2024-06-04
Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion
Not yet recruitingNCT07552610
Xuanwu Hospital, BeijingAcute Ischemic Stroke, Large Vessel Occlusion, Neutrophil Extracellular Trap Formation +1
Start: 2026-06-01End: 2029-05-01Target: 868Updated: 2026-04-27

Related Papers